Compare Stocks: OSTX, ABEO, CATX, and SABS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABEO Abeona Therapeutics	$5.45 -1.5%	$6.18	$4.00 ▼ $7.65	$312.09M	1.33	1.28 million shs	172,885 shs
CATX Perspective Therapeutics	$2.52 -4.0%	$3.02	$1.96 ▼ $6.16	$287.09M	1.8	2.24 million shs	285,277 shs
OSTX OS Therapies	$1.64 -0.6%	$1.64	$1.15 ▼ $2.25	$75.47M	-0.68	647,019 shs	68,653 shs
SABS SAB Biotherapeutics	$3.35 -1.2%	$3.64	$1.85 ▼ $5.15	$304.80M	0.53	625,492 shs	93,050 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABEO Abeona Therapeutics	-4.98%	+2.98%	-8.75%	-0.54%	+0.36%
CATX Perspective Therapeutics	-11.49%	-2.96%	-17.87%	-12.67%	-17.35%
OSTX OS Therapies	-6.78%	-5.71%	+6.45%	-8.33%	-25.68%
SABS SAB Biotherapeutics	-3.14%	0.00%	-6.35%	-12.40%	+50.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABEO Abeona Therapeutics	$5.45 -1.5%	$6.18	$4.00 ▼ $7.65	$312.09M	1.33	1.28 million shs	172,885 shs
CATX Perspective Therapeutics	$2.52 -4.0%	$3.02	$1.96 ▼ $6.16	$287.09M	1.8	2.24 million shs	285,277 shs
OSTX OS Therapies	$1.64 -0.6%	$1.64	$1.15 ▼ $2.25	$75.47M	-0.68	647,019 shs	68,653 shs
SABS SAB Biotherapeutics	$3.35 -1.2%	$3.64	$1.85 ▼ $5.15	$304.80M	0.53	625,492 shs	93,050 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABEO Abeona Therapeutics	-4.98%	+2.98%	-8.75%	-0.54%	+0.36%
CATX Perspective Therapeutics	-11.49%	-2.96%	-17.87%	-12.67%	-17.35%
OSTX OS Therapies	-6.78%	-5.71%	+6.45%	-8.33%	-25.68%
SABS SAB Biotherapeutics	-3.14%	0.00%	-6.35%	-12.40%	+50.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABEO Abeona Therapeutics	2.60	Moderate Buy	$21.00	285.60% Upside
CATX Perspective Therapeutics	3.00	Buy	$11.50	357.26% Upside
OSTX OS Therapies	2.75	Moderate Buy	$13.33	713.01% Upside
SABS SAB Biotherapeutics	2.73	Moderate Buy	$12.00	258.21% Upside

Current Analyst Ratings Breakdown

Latest OSTX, ABEO, CATX, and SABS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/18/2026	CATX Perspective Therapeutics	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
9/18/2026	ABEO Abeona Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$28.00 ➝ $30.00
9/17/2026	SABS SAB Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/17/2026	ABEO Abeona Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$17.00
9/17/2026	ABEO Abeona Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$17.00
9/15/2026	CATX Perspective Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$11.00
9/3/2026	SABS SAB Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/20/2026	SABS SAB Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/18/2026	CATX Perspective Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Outperform	$11.00
8/18/2026	CATX Perspective Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/17/2026	ABEO Abeona Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)

(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABEO Abeona Therapeutics	$5.82M	53.51	N/A	N/A	$2.94 per share	1.85
CATX Perspective Therapeutics	$880K	326.24	N/A	N/A	$2.79 per share	0.90
OSTX OS Therapies	N/A	N/A	N/A	N/A	($0.17) per share	N/A
SABS SAB Biotherapeutics	N/A	N/A	$0.33 per share	10.24	$3.18 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABEO Abeona Therapeutics	$71.18M	-$1.09	N/A	N/A	N/A	N/A	-41.69%	-30.36%	11/11/2026 (Estimated)
CATX Perspective Therapeutics	-$103.12M	N/A	N/A	N/A	N/A	-28,467.97%	-41.92%	-34.42%	11/9/2026 (Estimated)
OSTX OS Therapies	-$28.75M	-$0.79	N/A	2.78	N/A	N/A	N/A	-477.37%	N/A
SABS SAB Biotherapeutics	$13.27M	-$1.30	N/A	N/A	N/A	N/A	-6.74%	-6.06%	11/13/2026 (Estimated)

Latest OSTX, ABEO, CATX, and SABS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	OSTX OS Therapies	N/A	-$0.20	N/A	-$0.20	N/A	N/A
8/13/2026	Q2 2026	ABEO Abeona Therapeutics	-$0.2317	-$0.35	-$0.1183	-$0.35	$12.24 million	$11.38 million
8/10/2026	Q2 2026	CATX Perspective Therapeutics	-$0.2511	-$0.22	+$0.0311	-$0.22	$0.09 million	$0.08 million
8/6/2026	Q2 2026	SABS SAB Biotherapeutics	-$0.2830	-$0.28	+$0.0030	-$0.28	$0.13 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABEO Abeona Therapeutics	N/A	N/A	N/A	N/A	N/A
CATX Perspective Therapeutics	N/A	N/A	N/A	N/A	N/A
OSTX OS Therapies	N/A	N/A	N/A	N/A	N/A
SABS SAB Biotherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABEO Abeona Therapeutics	0.01	6.63	6.40
CATX Perspective Therapeutics	N/A	6.61	6.61
OSTX OS Therapies	N/A	0.18	0.18
SABS SAB Biotherapeutics	0.01	9.22	9.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABEO Abeona Therapeutics	80.56%
CATX Perspective Therapeutics	54.66%
OSTX OS Therapies	N/A
SABS SAB Biotherapeutics	7.82%

Insider Ownership

Company	Insider Ownership
ABEO Abeona Therapeutics	7.10%
CATX Perspective Therapeutics	2.99%
OSTX OS Therapies	9.60%
SABS SAB Biotherapeutics	7.39%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABEO Abeona Therapeutics	226	57.18 million	53.12 million	Optionable
CATX Perspective Therapeutics	166	114.15 million	110.74 million	Optionable
OSTX OS Therapies	5	46.13 million	41.70 million	N/A
SABS SAB Biotherapeutics	86	90.99 million	84.26 million	Not Optionable

OSTX, ABEO, CATX, and SABS Headlines

Recent News About These Companies

SAB Biotherapeutics, Inc. Announces Presentations Of SAB-142 Data At The 62nd Annual Meeting Of The European Association For The Study Of Diabetes

September 22 at 3:11 PM | marketscreener.comM

SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes

September 22 at 8:30 AM | globenewswire.com

SAB Biotherapeutics, Inc. (SABS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

September 10, 2026 | seekingalpha.com

SAB Biotherapeutics, Inc. (NASDAQ:SABS) Given Consensus Rating of "Moderate Buy" by Brokerages

September 5, 2026 | marketbeat.com

SAB BIO to Participate in Upcoming Investor Conferences

September 1, 2026 | globenewswire.com

375,000 Shares in SAB Biotherapeutics, Inc. $SABS Purchased by AWM Investment Company Inc.

August 26, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (DNLI) and SAB Biotherapeutics (SABS)

August 8, 2026 | theglobeandmail.com

SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights

August 6, 2026 | globenewswire.com

SAB Biotherapeutics (SABS) and Breakthrough T1D Award Research Grant For SAB-142 Assessment

July 15, 2026 | finance.yahoo.com

SAB Biotherapeutics advances SAB-142 Type 1 diabetes trial

July 12, 2026 | theglobeandmail.com

SAB Biotherapeutics, Inc.: Breakthrough T1D Awards Grant to Support PRISE-hATG Study of SAB-142 in Stage 3 Type 1 Diabetes

July 7, 2026 | finanznachrichten.de

Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes

July 7, 2026 | globenewswire.com

Why Is H.C. Wainwright Bullish On SAB Biotherapeutics (SABS) With $10 Price Target?

July 6, 2026 | finance.yahoo.com

SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting

May 29, 2026 | finance.yahoo.com

SAB BIO to Present Data on SAB-142 at The American Diabetes Association's 2026 Scientific Sessions and FOCIS 2026 Annual Meeting

May 29, 2026 | globenewswire.com

Citigroup initiates coverage of SAB Biotherapeutics (SABS) with buy recommendation

May 23, 2026 | msn.com

Why SAB Biotherapeutics, Inc.’s (SABS) Stock Is Up 7.01%

May 21, 2026 | aaii.comA

SAB Biotherapeutics Inc SABS

May 20, 2026 | morningstar.comM

Jefferies initiates coverage of SAB Biotherapeutics (SABS) with buy recommendation

May 20, 2026 | msn.com

SAB Biotherapeutics Signs Manufacturing Pact for SAB-142

May 16, 2026 | theglobeandmail.com

We Think SAB Biotherapeutics (NASDAQ:SABS) Needs To Drive Business Growth Carefully

May 16, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OSTX, ABEO, CATX, and SABS Company Descriptions

Abeona Therapeutics NASDAQ:ABEO

$5.45 -0.08 (-1.52%)

As of 10:49 AM Eastern

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Perspective Therapeutics NYSEAMERICAN:CATX

$2.52 -0.11 (-4.01%)

As of 10:49 AM Eastern

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

OS Therapies NYSEAMERICAN:OSTX

$1.64 -0.01 (-0.61%)

As of 10:47 AM Eastern

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

SAB Biotherapeutics NASDAQ:SABS

$3.35 -0.04 (-1.18%)

As of 10:49 AM Eastern

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OSTX, ABEO, CATX, and SABS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OSTX, ABEO, CATX, and SABS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OSTX, ABEO, CATX, and SABS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

OSTX, ABEO, CATX, and SABS Company Descriptions

Abeona Therapeutics NASDAQ:ABEO

Perspective Therapeutics NYSEAMERICAN:CATX

OS Therapies NYSEAMERICAN:OSTX

SAB Biotherapeutics NASDAQ:SABS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OSTX, ABEO, CATX, and SABS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OSTX, ABEO, CATX, and SABS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OSTX, ABEO, CATX, and SABS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

OSTX, ABEO, CATX, and SABS Company Descriptions

Abeona Therapeutics NASDAQ:ABEO

Perspective Therapeutics NYSEAMERICAN:CATX

OS Therapies NYSEAMERICAN:OSTX

SAB Biotherapeutics NASDAQ:SABS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools